Laigo Bio, a Dutch biotech company, has announced the closing of a €17 million seed funding round to accelerate the development of its SureTACs platform.

SureTACs Technology

The SureTACs platform is designed to address membrane proteins, a notoriously difficult drug target. Instead of blocking these proteins, as many traditional drugs do, SureTACs engineers them out of existence. This innovative approach could open new avenues for treating previously incurable diseases.

Funding

The funding round was co-led by Biovance Capital and Kurma Partners. This investment will allow Laigo Bio to expand its research and development activities and advance its drug pipeline.